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Diabetes mellitus is a common endocrine disorder characterized by hyperglycemia and long-term 
complications affecting the eyes, nerves, blood vessels, skin and kidneys. Increased glycation of 
proteins and accumulation of advanced glycation endproducts (AGEPs) have been implicated in the 
pathogenesis of diabetic complications. Glycation and AGEP formation are also accompanied by the 
formation of free radicals via autoxidation of glucose and glycated proteins. Since this plant Eremurus 
persicus is used as an antidiabetic agent in Iranian traditional medicine, we were prompted to evaluate 
the antiglycation activity of this species. Here, we reported the isolation of a known compound, 5,6,7-
trimethoxy-coumarinfor the first time for the antiglycation properties of this plant. 
 





Diabetes mellitus is an endocrine disorder characterized 
by chronic hyperglycemia which results to a deficiency or 
resistance to insulin. Diabetes affects 1 to 2% of the 
population, and there are about 100 million people 
worldwide. This figure is expected to double over the next 
10 to 15 years. Individuals affected by diabetes are prone 
to complications such as retinopathy, cataract, neuro-
pathy, atherosclerosis, nephropathy, embryopathy and 
wounds (Muhammed and Nessar, 2006). 
Non-enzymatic glycosylation (glycation) between 
reducing sugar and free amino group of proteins, also 
known as Millard reaction, leads to the formation of 
glycated protein termed Amadori product. Further re-
arrangement, oxidation and reduction of the Amadori 
products result in the formation of several advanced 
glycation endproducts (AGEs) such as pentosidine, 
carboxymethyllysine, crossline and pyralline. Some of 
these products can react with a nearby free amino group 
and form crosslinking between proteins (Ulrich and 
Cerami, 2001). The crosslinked protein, such as 




*Corresponding author. E-mail: asgarpanah@iaups.ac.ir Tel: 
22640051. Fax: 22602059.  
conditions found in patients with diabetes and aging, 
such as arterial stiffness and decreased myocardial com-
pliance, resulting from the loss of collagen elasticity 
(Singh et al., 2001; Aronson, 2003). Thus, agents that 
inhibit the formation of AGEs are purported to have 
therapeutic potentials in patients with diabetes and age-
related diseases. 
The oxidation process is believed to play an important 
role in AGEs formation. Further oxidation of Amadori 
product leads to the formation of intermediate carbonyl 
compounds that can react with the nearby lysine or 
arginine residues to form protein crosslink and AGEs. 
The reactive carbonyl compounds may also be generated 
from the metal ion-catalyzed autooxidation of glucose 
(Rahbar and Figarola, 2003; Voziyan et al., 2003). 
Therefore, agents with antioxidative or metal-chelating 
property may retard the process of AGEs formation by 
preventing further oxidation of Amadori product and 
metal-catalyzed glucose oxidation (Jedsadayanmata, 
2005). 
Eremurus persicus (Liliaceae) locally called "Serish", is 
widely distributed in south, east and west of Iran. It is 
traditionally used for the treatment of liver and stomach 
disorders, constipation and diabetes. Since this plant is 
traditionally used in patients with diabetes, we were 
prompted  to  investigate  the antiglycation   activity  of  E.  

























persicus. Here, we reported 5,6,7-trimethoxy-coumarin 
(Figure 1) as the active compound for the antiglycation 
property of this plant. 
 
 
MATERIALS AND METHODS 
 
Chemicals and general experimental procedure 
 
BSA (bovine serum albumin) was purchased from the Research 
Organics Cleveland, USA, while other chemicals: glucose 
anhydrous, trichloroacetic acid (TCA), sodium azide (NaN3), 
dimethyl sulfoxide (DMSO), sodium dihydrogen phosphate 
(Na2HPO4), potassium chloride (KCl), potassium dihydrogen 
phosphate (KH2PO4) and sodium hydroxide (NaOH) were 
purchased from Sigma Aldrich. 
Sodium phosphate buffer (pH 7.4) was prepared by mixing 
Na2HPO4 and NaH2PO4 (67 mM) containing sodium azide (3 mM), 
phosphate buffer saline (PBS) (PH 10) was prepared by mixing 
NaCl (137 mM) + Na2HPO4 (8.1 mM) + KCl (2.68 mM) + KH2PO4 
(1.47 mM) at pH 10 and was adjusted with NaOH (0.25 mM), while 
BSA (10 mg/ml) and glucose anhydrous (50 mg/ml) solutions were 
prepared in sodium phosphate buffer. 
The ¹H-NMR and ¹³C-NMR were recorded on a Bruker AMX 300 
NMR instruments using the UNIX data solvent. ¹H-¹³C HMBC and 
HMQC were recorded at 500 MHz (proton) and 125 MHz (carbon), 
respectively. 
The plant, E. persicus (Liliaceae) was collected from Gol-
payegan, Isfahan province, Iran, in May 2010, and identified by Dr. 
Gh. R. Amin at the Department of Pharmacognosy, Faculty of 
Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.  
A voucher specimen (No. 197) has been deposited in the 
herbarium of the Department of Pharmacognosy, Pharmaceutical 





The air dried flowering aerial parts of E. persicus (2 kg) was 
exhaustively extracted by maceration with methanol (3 x 4 L). The 
extract was evaporated to yield the residue (240 g) which was 
partitioned between water (18 g), petroleum ether (52 g), CHCl3 (95 
g) and EtOAc (70 g). The CHCl3 fraction had significant anti-
glycation, so we subjected it to silica gel chromatography using 
petroleum ether with a gradient of CHCl3 up to 100% and followed 





Table 1. ¹H-NMR (CDCl3) data of 5,6,7-trimethoxy-coumarin. 
 
 Position  ¹H-NMR 
C (2) - 
H–C (3)  7.88 (1H, d, J=9.6) 
H–C (4)  6.18 (1H, d, J=9.6) 
C (5) - 
C (6) - 
C (7) - 
C (8) 6.57 (1H, s) 
C (9) - 
C (10) - 
MeO (11) 3.99 (3H, s) 
MeO (12) 3.82 (3H, s) 
MeO (13) 3.88 (3H, s) 
 




antiglycation activity, and contained a major spot (Rf = 0.37) on TLC 
using solvent system petroleum ether-acetone, 50:50. This spot 
showed blue-green fluorescence under UV 365 nm light with 5% 
KOH. We isolated this compound by preparative TLC method and 
solvent system petroleum ether-acetone (50:50). It was crystallized 
from methanol (48 mg) and identified as 5,6,7-trimethoxy coumarin 
(Tables 1 and 2). It exhibited a very good antiglycation activity. 
 
 
In vitro glycation assay 
 
60 l of sample was prepared by dissolving in DMSO and the 
sample mixture (20 l BSA + 20 l of glucose anhydrous + 20 l 
test sample). The glycated control contained 20 l BSA + 20 l 
glucose + 20 l sodium phosphate buffer, while blank control 
contained 20 l BSA and 40 l sodium phosphate buffer. After 
incubation in 96 well plates at 37°C for 7 days, samples were taken 
out and cooled at room temperature. After incubation, 60 l 100% 
TCA was added to each well and centrifuged (15000 rpm) for 4 min 
at 4°C. After agitation and centrifugation at 14000 rpm for 4 min, the 
supernatant containing glucose, inhibitor and interfering substance 
was removed and pellet contained AGE-BSA which was dissolved 
in PBS. Assessment of fluorescence spectrum (ex. 370 nm), and 
change in fluorescence intensity (ex. 370 to 440 nm) based on 
AGEs were monitored by using spectrofluorimeter RF-1500 
(Shimadzu, Japan). Rutin was used as the standard inhibitor. The 
comparison of fluorescence intensity at 370 nm excitation and 
emission at 440 nm was obtained by using spectrofluorimeter. 
Percentage inhibition was calculated using the following formula: 
 
Inhibition (%) = 100 – [OD (test) / OD (blank)] x 100 
 
 
RESULTS AND DISCUSSION 
 
The active compound isolated had pale yellow crystals 
and was identified as 5,6,7-trimethoxy-coumarin. Here, 
we reported the 1H-NMR and 13C-NMR data of this com-
pound. 5,6,7-trimethoxy-coumarin exhibited a good 
antiglycation activity. It was observed that this compound 
at 3 mM concentration showed 75% inhibition, while the 
standard inhibitor, rutin showed 83% inhibition. 





agents may retard the process of AGEs formation by 
preventing further oxidation of Amadori product and 
metal-catalyzed glucose oxidation, further in vivo and in 
vitro tests to investigate the antioxidant properties for 
5,6,7-trimethoxy-coumarin are recommended. Also, in 
vivo confirmatory tests to evaluate the anti hyperglycemic 
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